Al Amyloidosis
📧 Sign up to get email alerts when something new happens for Al Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
A European registry and sample-sharing network called EUREKA has been established to promote the diagnosis and management of AL amyloidosis,…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
A clinical trial in Italy (ProDigALIty) aims to promote diagnosis and management of AL amyloidosis and related plasma cell disorders and is …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Registry of AL Amyloidosis (ReAL)
This entry describes the A Registry of AL Amyloidosis (ReAL), a clinical trial registry that is currently recruiting participants with AL am…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis [Phase 2]
An update on a Phase 2 clinical trial evaluating daratumumab-based therapies in participants with AL amyloidosis; the study is currently act…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis [Phase 1]
This Phase 1 study of JNJ-79635322 in relapsed or refractory multiple myeloma and previously treated AL amyloidosis is currently recruiting.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis [Phase 1]
A Phase 1 clinical trial evaluating the combination of venetoclax, ixazomib citrate (MLN9708), and dexamethasone for relapsed or refractory …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) [Phase 3]
Phase 3 CARES trial update for CAEL-101 in Mayo Stage IIIa AL amyloidosis. The study is currently active and not recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: CAR-NK Therapy for Cardiac Amyloidosis [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial of CAR-NK therapy for light-chain (AL) cardiac amyloidosis, currently not recruiting.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial [Phase 2]
A phase 2 clinical trial (EMILIA) is evaluating daratumumab as maintenance therapy to improve survival in patients with AL amyloidosis; the …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis [Phase 1]
Phase 1 clinical trial update for GC012F CAR-T therapy targeting CD19 and BCMA in Chinese participants with relapsed or refractory AL amyloi…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
This document announces an ongoing registry and sample resource at Ohio State University Comprehensive Cancer Center for plasma cell dyscras…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) [NA]
A clinical trial is ongoing to optimize first-line treatment for systemic AL amyloidosis with the t(11;14) translocation; the study is curre…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis [Phase 1, Phase 2]
Clinical trial evaluating elranatamab in adults with relapsed or refractory AL amyloidosis (Phase 1/2); currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
This clinical trial entry describes an ongoing study investigating how N-glycosylation contributes to AL amyloidosis, including its molecula…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
A clinical trial evaluating the pathologic role of the gene IGLV1-44 in AL amyloidosis and POEMS syndrome is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis [Phase 3]
A Phase 3 study evaluating Coagadex for Acquired Factor X Deficiency associated with AL amyloidosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab [Phase 2]
Phase 2 trial evaluating Daratumumab, Pomalidomide, and Dexamethasone (DPd) for relapsed/refractory light chain (AL) amyloidosis in patients…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis [Phase 1]
This is a Phase 1 clinical trial evaluating a three-drug regimen (daratumumab, ixazomib, and dexamethasone) for AL amyloidosis; the study is…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: BE.Amycon Biobank & Data Registry UZ Leuven
A clinical trial registry update for the BE.Amycon Biobank & Data Registry at Universitaire Ziekenhuizen KU Leuven, focusing on amyloidosis …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis [Phase 1]
Phase 1 clinical trial evaluating upfront use of isatuximab for high-risk AL amyloidosis, sponsored by Emory University. The study status is…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) [Phase 2]
Phase 2 clinical trial evaluating minimal residual disease–driven deferral of transplant in dysproteinemia, including multiple myeloma and A…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [Phase 3]
This Clinical Trial Update describes a Phase 3 study evaluating the efficacy of the PET tracer Florbetaben (18F) for diagnosing cardiac AL a…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis [Phase 2]
A Phase 2 clinical trial evaluating whether siltuximab can reduce symptom burden after autologous stem cell transplantation in patients with…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. [Phase 1]
Phase 1 study evaluating Captisol-enabled melphalan pharmacokinetics in patients with multiple myeloma or AL amyloidosis undergoing autologo…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis [Phase 3]
Phase 3 trial update comparing Dara-VCD chemotherapy with autologous stem cell transplant versus Dara-VCD chemotherapy alone in newly diagno…